KeloidNCT07420166
Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids
A study testing Triamcinolone Acetonide and Verapamil Hydrochloride in people with Keloid, run by Muhammad Aamir Latif at 1 site in Pakistan.
Trial summary
The paucity of local literature regarding the comparison of intralesional verapamil with intralesional triamcinolone acetonide led this study to be carried out with the objective of comparing the clinical effectiveness of intralesional triamcinolone acetonide and intralesional verapamil hydrochloride in patients with… Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Keloid
- What is being tested?
- Triamcinolone Acetonide and Verapamil Hydrochloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jan 2025to 30 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Either gender
- Aged between 20 and 60 years
- With keloids
- Benign dermal growths
- Scar length not exceeding 5 centimeters
- Keloid duration of five years or less
- A baseline Vancouver Scar Scale score of 5 or more
Who cannot join
- Pregnant or lactating women
- A family history of keloids
- Diagnosed with conditions such as acromegaly, diabetes mellitus, or congestive cardiac disease
- a history of thyroidectomy
- Current or recent use of isotretinoin or anabolic steroids, as determined by history, physical examination, blood glucose analysis, and electrocardiography
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Bahawal Victoria Hospital/Quaid-e-Azam Medical College
Bahawalpur, Punjab Province, 63100
About this study
Official title: Comparison of the Outcome of Treatment of Intralesional Triamcinolone Acetonide With Intralesional Verapamil Hydrochloride in Patients Presenting With Keloid at Tertiary Care Hospital, Bahawalpur.
The paucity of local literature regarding the comparison of intralesional verapamil with intralesional triamcinolone acetonide led this study to be carried out with the objective of comparing the clinical effectiveness of intralesional triamcinolone acetonide and intralesional verapamil hydrochloride in patients with keloids.
Read the detailed description
Although the anti-inflammatory and scar-enhancing properties of corticosteroids on hypertrophic scars and keloids have been investigated and documented thoroughly. There are many different treatments for keloids nowadays; each method has its advantages and disadvantages, and the results also vary depending on each study. Moreover, local data to address this issue is also scarce. The findings of this study would not add to the existing stats, but comparing the outcomes of both the drugs would also guide clinicians towards better management of keloids by choosing the more appropriate treatment.
- Conditions
- Keloid
- Being tested
- Triamcinolone Acetonide, Verapamil Hydrochloride
- Medical subject headings
- Keloid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Triamcinolone AcetonideDrug
Patients received intralesional triamcinolone acetonide (20 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.
Verapamil HydrochlorideDrug
Patients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.
| Study group | Role | What they receive |
|---|---|---|
| Triamcinolone Group | Experimental | Patients received intralesional triamcinolone acetonide (20 mg/mL) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion. Receives: Drug: Triamcinolone Acetonide |
| Verapamil Group | Experimental | Patients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion. Receives: Drug: Verapamil Hydrochloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Scar assessment
Using the Vancouver Scar Scale, height, vascularity, pliability, and pigmentation were assessed at baseline and compared with post-treatment measures at 24 weeks. A score closer to 0 was deemed as better vascularity (not red), low pigmentation, high pliability (soft), and low thickness.
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study start1 Jan 2025
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for KeloidStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Muhammad Aamir Latif
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Muhammad Aamir Latif, RESnTEC, Institute of Research
- Investigators
- Bakhtawar, Principal investigator, Bahawal Victoria Hospital/Quaid-e-Azam Medical College, BahawalpurSalman Ashraf, FCPS, Study director, Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07420166
- Sponsor's protocol ID
- Dr-Bakhtawar-BVH
- Status last verified
- Feb 2026
- First submitted
- 12 Feb 2026
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data can be shared on a reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Outcome of Treatment of Intralesional Triamcinolone Acetonide With Intralesional Verapamil Hydrochloride in Patients Presenting With Keloid at Tertiary Care Hospital, Bahawalpur.
- ClinicalTrials.gov ID
- NCT07420166
- Acronym / sponsor ID
- Dr-Bakhtawar-BVH
- Conditions
- Keloid
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Muhammad Aamir LatifUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The paucity of local literature regarding the comparison of intralesional verapamil with intralesional triamcinolone acetonide led this study to be carried out with the objective of comparing the clinical effectiveness of intralesional triamcinolone acetonide and intralesional verapamil hydrochloride in patients with keloids.
Detailed description
Although the anti-inflammatory and scar-enhancing properties of corticosteroids on hypertrophic scars and keloids have been investigated and documented thoroughly. There are many different treatments for keloids nowadays; each method has its advantages and disadvantages, and the results also vary depending on each study. Moreover, local data to address this issue is also scarce. The findings of this study would not add to the existing stats, but comparing the outcomes of both the drugs would also guide clinicians towards better management of keloids by choosing the more appropriate treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Triamcinolone Group | Experimental | Drug: Triamcinolone AcetonidePatients received intralesional triamcinolone acetonide (20 mg/mL) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion. |
| Verapamil Group | Experimental | Drug: Verapamil HydrochloridePatients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion. |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Either gender
- Aged between 20 and 60 years
- With keloids
- Benign dermal growths
- Scar length not exceeding 5 centimeters
Key exclusion criteria (5 listed)
- Pregnant or lactating women
- A family history of keloids
- Diagnosed with conditions such as acromegaly, diabetes mellitus, or congestive cardiac disease
- a history of thyroidectomy
- Current or recent use of isotretinoin or anabolic steroids, as determined by history, physical examination, blood glucose analysis, and electrocardiography
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Triamcinolone AcetonidePatients received intralesional triamcinolone acetonide (20 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion. | Drug | Triamcinolone Group |
| Verapamil HydrochloridePatients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion. | Drug | Verapamil Group |
Primary outcome
Scar assessment
Time frame: 24 weeks
Using the Vancouver Scar Scale, height, vascularity, pliability, and pigmentation were assessed at baseline and compared with post-treatment measures at 24 weeks. A score closer to 0 was deemed as better vascularity (not red), low pigmentation, high pliability (soft), and low thickness.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
- Individual participant dataSharing planned: No. Data can be shared on a reasonable request.
Related trials for Keloid
Not yet recruiting
Fractional Radiofrequency With Streroids Versus Fractional CO2 Laser With Steroids in the Treatment of Keloids
Keloids
Active, not recruiting
Transdermal Versus Intralesional Betamethasone for Keloids
Keloid
RecruitingPhase 2
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
Keloid
Recruiting
Radiotherapy for Keloids
Keloid
Not yet recruitingPhase 2
siRNA Microneedle Patches for Ear Keloid Post-Surgical Scars
Keloid of Ear Lobe
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bakhtawar principal investigator
Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur
Salman Ashraf, FCPS study director
Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Triamcinolone Acetonide and Verapamil Hydrochloride in people with Keloid, run by Muhammad Aamir Latif at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Scar assessment (time frame: 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.